Autres langues Vaccinex, Inc.

Actions

VCNX

US9186403013

Marché Fermé - Nasdaq Autres places de cotation 22:30:00 26/06/2024			Varia. 5j.	Varia. 1 janv.
6 ^USD	+3,63 %		-2,12 %	-35,53 %

06/06	Vaccinex annonce la fin de la visite du dernier patient de l'étude randomisée de phase 1b/2 SIGNAL-AD sur le traitement de la maladie d'Alzheimer par le pepinemab	CI
15/05	Vaccinex, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer's disease	07/06
Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer’s Disease	06/06
Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer?s Disease	06/06
Vaccinex : ASCO Conference Presentation	01/06
Earnings Flash (VCNX) VACCINEX Reports Q1 Revenue $104,000	16/05
Vaccinex Reports First Quarter 2024 Financial Results and Provides Corporate Update	16/05
Vaccinex, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	15/05
VACCINEXPAR : 12th Alzheimer’s & Parkinson’s Drug Development Summit Presentation	26/04
Vaccinex, Inc. announced that it has received $1.75 million in funding	12/04
Vaccinex Reports 2023 Financial Results and Provides Corporate Update	02/04
Vaccinex, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02/04
Vaccinex, Inc. announced that it expects to receive $1.75 million in funding	29/03
Vaccinex, Inc. announced that it has received $1.240737 million in funding from FCMI Parent Co., Vaccinex, L.L.C	28/03
Vaccinex, Inc. Announces $1.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules	27/03
Vaccinex, Inc. announced that it expects to receive $1.240737 million in funding from FCMI Parent Co., Vaccinex, L.L.C	27/03
Vaccinex, Inc. announced that it expects to receive $1.49961 million in funding	27/03
Vaccinex, Inc. Announces Chief Financial Officer Changes, Effective March 14, 2024	04/03
Vaccinex, Inc. Announces Executive Changes, Effective March 14, 2024	04/03
Sector Update: Health Care Stocks Slipping Wednesday Afternoon	21/02
Vaccinex Shares Rise as Company Announces Eight New Deals for Antibody Discovery Platform	21/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Vaccinex, Inc.

Actions

VCNX

US9186403013

Autres langues

Filtres